title: The effect of oral micronized progesterone on hormonal and metabolic parameters in anovulatory patients with polycystic ovary syndrome.
abstract: OBJECTIVE
  To investigate the effects of oral natural micronized P on hormonal and metabolic parameters in patients with polycystic ovary syndrome (PCOS) and to answer the clinical question whether induction of withdrawal bleeding is a necessity for the comparison of hormonal and metabolic data in subjects with PCOS.
  
  
  METHODS
  Prospective clinical study.
  
  
  METHODS
  Academic medical center.
  
  
  METHODS
  Twenty-eight reproductive-aged women with PCOS.
  
  
  METHODS
  Blood sampling was collected at baseline, after 7 days of oral natural micronized P (200 mg) administration, and after withdrawal bleeding. At these three stages hormonal parameters and homeostasis assessment model (HOMA-IR) index were assessed in all patients.
  
  
  RESULTS
  Oral natural micronized P administration did not alter significantly insulin sensitivity index and androgen levels; however, LH was decreased when postbleeding values were compared to baseline. Nevertheless, after oral natural micronized P administration, P and 17alpha-hydroxyprogesterone (17-OHP) concentrations were increased, and HOMA-IR was decreased, whereas androgens levels were not altered, in comparison with baseline.
  
  
  CONCLUSIONS
  The induction of withdrawal bleeding, with this regimen, does not appear to be a necessity for the assessment of hormonal and metabolic profile in anovulatory women with PCOS.
authors.affiliation: First Department of Medicine, Endocrine Section, University of Athens Medical School, Athens, Greece.
authors.forename: Sarantis
authors.initials: S
authors.lastname: Livadas
authors.forename: Georgios
authors.initials: G
authors.lastname: Boutzios
authors.forename: Fragiskos
authors.initials: F
authors.lastname: Economou
authors.forename: Krystallenia
authors.initials: K
authors.lastname: Alexandraki
authors.forename: Xenofon
authors.initials: X
authors.lastname: Xyrafis
authors.forename: Maria
authors.initials: M
authors.lastname: Christou
authors.forename: Aristea
authors.initials: A
authors.lastname: Zerva
authors.forename: Athanasios
authors.initials: A
authors.lastname: Karachalios
authors.forename: Evangelia
authors.initials: E
authors.lastname: Tantalaki
authors.forename: Evanthia
authors.initials: E
authors.lastname: Diamanti-Kandarakis
mesh_terms: D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D000858:Anovulation / Q000150:complications / Q000188:drug therapy* / Q000378:metabolism*; D005260:Female; D006801:Humans; D007986:Luteinizing Hormone / Q000097:blood; D011085:Polycystic Ovary Syndrome / Q000150:complications / Q000188:drug therapy* / Q000378:metabolism*; D011374:Progesterone / Q000008:administration & dosage* / Q000097:blood / Q000737:chemistry*; D011446:Prospective Studies; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D011374:Progesterone; D007986:Luteinizing Hormone